Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 2, 2012, Pages 427-433

  Okamoto, Isamu ^a   Yoshioka, Hiroshige ^b   Takeda, Koji ^c   Satouchi, Miyako ^d   Yamamoto, Nobuyuki ^e   Seto, Takashi ^f   Kasahara, Kazuo ^g   Miyazaki, Masaki ^a   Kitamura, Ryuichi ^h   Ohyama, Akio ^h   Hokoda, Noriko ⁱ   Nakayama, Hiroshi ⁱ   Yoshihara, Eiji ⁱ   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d HYOGO CANCER CENTER   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^h Pharmacology and Pharmacokinetics Department of Pharmacy   (Japan)

ⁱ TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Angiogenesis; Non small cell lung cancer; Phase I

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; ORANTINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHOLECYSTITIS; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK DISEASE; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; PERICARDITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84858334676     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318238154d     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
3. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18. (Pubitemid 43261975)
4. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-2049. (Pubitemid 351656458)
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
6. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
7. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-1809.
8. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-4160. (Pubitemid 30636598)
9. Laird AD, Christensen JG, Li G, et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002;16:681-690. (Pubitemid 34465432)
10. Marzola P, Degrassi A, Calderan L, et al. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 2004;10:739-750. (Pubitemid 38174012)
11. Yorozuya K, Kubota T, Watanabe M, et al. TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis. Oncol Rep 2005;14:677-682.
12. Yamamoto M, Kikuchi H, Ohta M, et al. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res 2008;68:9754-9762.
13. Naumova E, Ubezio P, Garofalo A, et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 2006;12:1839-1849.
14. Murakami H, Ueda Y, Shimoyama T, et al. Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol 2011;67:1119-1128.
15. Ueda Y, Shimoyama T, Murakami H, et al. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:1101-1109.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18:317-323. (Pubitemid 46323100)
18. Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapynaive patients with advanced non-small-cell lung cancer: results of a West Japan Oncology Group study. J Clin Oncol 2010;28:5240-5246.
19. Kanai F, Yoshida H, Tateishi R, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011;67:315-324.
20. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599-606.
21. van der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991;21:242-261.
22. Shimokata T, Ando Y, Yasuda Y, et al. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci 2010;101:2601-2605.
23. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;12:3124-3129. (Pubitemid 43837360)
24. Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;376:517-519.
25. Feng Y, Wang W, Hu J, et al. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer. Anat Rec 2010;293:802-812.
26. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group study. Clin Cancer Res 2008;14:1407-1412. (Pubitemid 351413922)
27. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-3748.
28. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102: 8-18.